19:55 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes. AMBAR, which stands for Alzheimer Management by Albumin Replacement, was...
23:09 , Oct 29, 2018 |  BC Extra  |  Clinical News

Grifols' AMBAR approach slows disease progression in moderate Alzheimer’s

Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) reported Phase IIb/III data on its AMBAR approach to treat Alzheimer’s disease demonstrating evidence of mechanism and improvements in clinical outcomes. AMBAR, which stands for Alzheimer Management by Albumin Replacement, was...
08:00 , Nov 8, 1999 |  BioCentury  |  Tools & Techniques

Approved protein & antibody therapeutics

Approved protein & antibody therapeutics...